1,169 results on '"Marth, Christian"'
Search Results
2. Antibody–drug conjugates in ovarian cancer
3. Correction: Real-world prevalence of microsatellite instability testing and related status in women with advanced endometrial cancer in Europe
4. Cropsi study: Efficacy and safety of cryotherapy and cryocompression in the prevention of chemotherapy-induced peripheral neuropathy in patients with breast and gynecological cancer–A prospective, randomized trial
5. Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer
6. Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer
7. Verification of the prognostic precision of the new 2023 FIGO staging system in endometrial cancer patients – An international pooled analysis of three ESGO accredited centres
8. Prospective, randomized trial on efficacy and safety of cryotherapy and cryocompression therapy as prevention of chemotherapy-induced peripheral neuropathy.
9. PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial
10. Austria-based real-world data on bevacizumab in newly diagnosed epithelial ovarian cancer
11. An angiogenic tumor phenotype predicts poor prognosis in ovarian cancer
12. Causal analyses with target trial emulation for real-world evidence removed large self-inflicted biases: systematic bias assessment of ovarian cancer treatment effectiveness
13. Real-world treatment patterns and clinical outcomes from a retrospective chart review study of patients with recurrent or advanced endometrial cancer who progressed following prior systemic therapy in Europe
14. Maintenance Therapy with Aromatase Inhibitor in epithelial Ovarian Cancer (MATAO): study protocol of a randomized double-blinded placebo-controlled multi-center phase III Trial
15. The impact of COVID-19 pandemic on the rate of newly diagnosed gynecological and breast cancers: a tertiary center perspective
16. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup
17. Efficacy of an optimal ovarian cancer screening: a best-case scenario study based on real-world data
18. Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer
19. Integrated immunogenomic analyses of high-grade serous ovarian cancer reveal vulnerability to combination immunotherapy
20. Role of Hormonal Therapy in Advanced Stage Endometrial Cancer
21. Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer
22. Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2
23. ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma
24. Ovarian Cancer Stem Cell Heterogeneity
25. Intraperitoneale Chemotherapie in der Behandlung des Ovarial- und Tubenkarzinoms
26. Sexualität nach der Therapie gynäkologischer Malignome
27. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial
28. Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2− advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT
29. Perception of Labial Size and Objective Measurements-Is There a Correlation? A Cross-Sectional Study in a Cohort Not Seeking Labiaplasty
30. AGO-OVAR 28/ENGOT-ov57. Niraparib alone versus niraparib in combination with bevacizumab in patients with carboplatin-taxane-based chemotherapy in advanced ovarian cancer: a multicenter randomized phase III trial
31. Supplementary Figure S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
32. Supplementary Table S2 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
33. Data from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
34. TP008/#1500 Trial in progress: phase 2/3 study of navtemadlin as maintenance therapy in patients with advanced or recurrent endometrial cancer who responded to chemotherapy (ENGOT-EN21; GOG-3089)
35. Supplementary Appendix S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
36. Supplementary Data 1 from Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer
37. Data from Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer
38. #894 Real-world treatment patterns in recurrent or advanced endometrial cancer patients who initiated second-line systemic therapy in 5 European countries: a retrospective chart review study
39. #84 Trial in progress: a phase 2/3 study of navtemadlin as maintenance therapy in patients with advanced or recurrent endometrial cancer (EC) who responded to chemotherapy (ENGOT-En21 and GOG-3089)
40. #172 STREAM-I/AGO-OP.11/ENGOT-En22: evaluation of preoperative clinical and translational selection criteria for cytoreductive surgery in endometrial cancer – step 1 of the stream (surgical treatment in advanced and recurrent endometrial cancer management) initiative
41. #821 A data-driven disease burden model based on molecular classification in endometrial cancer patients in five european countries
42. #414 Evaluation of pegylated liposomal doxorubicin combined with trabectedin in uterine sarcomas
43. #888 Real-world treatment patterns in recurrent or advanced endometrial cancer patients who initiated first-line systemic therapy in 5 European countries: a retrospective chart review study
44. #809 Verification of the prognostic precision of the new 2023 FIGO staging system in endometrial cancer patients– an international pooled analysis of three ESGO accredited centers
45. #421 H3K4-demethylases JARID1A And JARID1B with an opposite effect on prognosis of ovarian cancer
46. #528 Efficacy of subsequent chemotherapy followed by PARP inhibitor maintenance in patients with advanced ovarian cancer in the phase III PAOLA-1/ENGOT-Ov25 trial
47. #1120 Durvalumab with paclitaxel/carboplatin + bevacizumab then maintenance durvalumab, bevacizumab + olaparib in patients with newly diagnosed advanced ovarian cancer without a tumour BRCA1/2 mutation: results from the DUO-O/ENGOT-Ov46/AGO-OVAR 23/GOG-3025 trial
48. Hopes and failures in front-line ovarian cancer therapy
49. Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001
50. European Society of Gynaecological Oncology quality indicators for the surgical treatment of endometrial carcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.